| PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer C Pantelidou, O Sonzogni, M De Oliveria Taveira, AK Mehta, A Kothari, ... Cancer discovery 9 (6), 722-737, 2019 | 489 | 2019 |
| A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors J Zhou, C Gelot, C Pantelidou, A Li, H Yücel, RE Davis, A Färkkilä, ... Nature cancer 2 (6), 598-610, 2021 | 209 | 2021 |
| Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer AK Mehta, EM Cheney, CA Hartl, C Pantelidou, M Oliwa, JA Castrillon, ... Nature cancer 2 (1), 66-82, 2021 | 143 | 2021 |
| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 138 | 2021 |
| The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells YKS Man, JA Davies, L Coughlan, C Pantelidou, A Blázquez-Moreno, ... Molecular cancer therapeutics 17 (2), 575-587, 2018 | 48 | 2018 |
| Regulation of glucocorticoid receptor activity by a stress responsive transcriptional cofactor L Davies, E Paraskevopoulou, M Sadeq, C Symeou, C Pantelidou, ... Molecular endocrinology 25 (1), 58-71, 2011 | 31 | 2011 |
| The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11 C Pantelidou, G Cherubini, NR Lemoine, G Halldén Oncotarget 7 (13), 15703, 2016 | 29 | 2016 |
| RETRACTED ARTICLE: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer J Patterson-Fortin, H Jadhav, C Pantelidou, T Phan, C Grochala, ... Nature Communications 14 (1), 1390, 2023 | 18 | 2023 |
| STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer C Pantelidou, H Jadhav, A Kothari, R Liu, GM Wulf, JL Guerriero, ... NPJ Breast Cancer 8 (1), 102, 2022 | 16 | 2022 |
| Site-specific and dose-dependent effects of glucocorticoid receptor phosphorylation in yeast Saccharomyces cerevisiae N Popovic, S Ruzdijic, DT Kanazir, A Niciforovic, M Adzic, ... Steroids 75 (6), 457-465, 2010 | 4 | 2010 |
| Retraction Note: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer J Patterson-Fortin, H Jadhav, C Pantelidou, T Phan, C Grochala, ... nature communications 14 (1), 8193, 2023 | | 2023 |
| Polymerase theta inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in BRCA-deficient cancers J Patterson-Fortin, H Jadhav, C Pantelidou, T Phan, C Grochala, ... Cancer Research 83 (7_Supplement), 6190-6190, 2023 | | 2023 |
| Polymerase theta inhibition synergizes with anti-PD-1 immunotherapy in BRCA2-deficient pancreatic ductal adenocarcinoma. J Patterson-Fortin, H Jadhav, C Pantelidou, T Phan, C Grochala, J Hao, ... CANCER RESEARCH 82 (22), 117-118, 2022 | | 2022 |
| Abstract C010: Polymerase theta inhibition synergizes with anti-PD-1 immunotherapy in BRCA2-deficient pancreatic ductal adenocarcinoma J Patterson-Fortin, H Jadhav, C Pantelidou, T Phan, C Grochala, J Hao, ... Cancer Research 82 (22_Supplement), C010-C010, 2022 | | 2022 |
| Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER+ breast cancer R Liu, C Pantelidou, H Jadhav, G Shapiro Cancer Research 82 (12_Supplement), 5649-5649, 2022 | | 2022 |
| STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer H Jadhav, C Pantelidou, A Kothari, R Liu, G Wulf, JL Guerriero, GI Shapiro Cancer Research 82 (12_Supplement), 1288-1288, 2022 | | 2022 |
| 860 Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer A Mehta, E Cheney, C Hartl, C Pantelidou, M Oliwa, J Castrillon, JR Lin, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | | 2020 |
| PARP inhibition modulates the infiltration, phenotype, and function of tumor-associated macrophages (TAMs) in BRCA-associated breast cancer and can be augmented by harnessing … AK Mehta, EM Cheney, JA Castrillon, JR Lin, MO Taveira, CA Hartl, ... CANCER IMMUNOLOGY RESEARCH 8 (3), 83-83, 2020 | | 2020 |
| Abstract A105: PARP inhibition modulates the infiltration, phenotype, and function of tumor-associated macrophages (TAMs) in BRCA-associated breast cancer and can be augmented … AK Mehta, EM Cheney, JA Castrillon, JR Lin, MO Taveira, CA Hartl, ... Cancer Immunology Research 8 (3_Supplement), A105-A105, 2020 | | 2020 |
| Abstract P5-04-01: PARP inhibition modulates the infiltration, phenotype and function of tumor-associated macrophages (TAMs) in BRCA-associated breast cancer and can be … JL Guerriero, AK Mehta, EM Cheney, JA Castrillon, JR Lin, MO Taveira, ... Cancer Research 80 (4_Supplement), P5-04-01-P5-04-01, 2020 | | 2020 |
